Mo1427 - An Important Nuance in Direct Acting Anti-Viral Hepatitis C Therapy: Glycemic Control

Background: Progranulin (GP88) is an 88-kDa glycoprotein growth factor with important biological effects in tumorigenesis and tumor survival. We investigated the usefulness of measuring serum GP88 (sGP88) levels as a predictive biomarker for hepatocellular carcinoma (HCC) in patients with viral hepatitis C after treatment with direct-acting antiviral (DAA) agents. Methods: We measured the sGP88 levels by using a sandwich enzyme-linked immunoassay from 67 healthy control subjects and 29 patients (20 patients who did not develop HCC and 9 patients who developed HCC after treatment) with viral hepatitis C after treatment with asunaprevir and daclatasvir. Results: The sGP88 levels of patients with chronic hepatitis C prior to antiviral treatment were significantly higher than those of healthy control subjects. After antiviral treatment, the sGP88 levels of patients who eventually developed HCC were significantly higher than those who did not develop HCC. The changes in the sGP88 levels before and after treatment in patients who developed HCC were significantly lower than those in patients who did not develop HCC. The cumulative incidence of HCC was significantly higher in either patients with high sGP88 levels after treatment or those with small changes of sGP88 levels pre- and post-treatment. Conclusions: Sustained high levels of sGP88 in patients treated with DAA agents are correlated with the risk of developing HCC.

Download Full-text

Effect of HCV Core Antigen and RNA Clearance during Therapy with Direct Acting Antivirals on Hepatic Stiffness Measured with Shear Wave Elastography in Patients with Chronic Viral Hepatitis C

Applied Sciences ◽

10.3390/app8020198 ◽

2018 ◽

Vol 8 (2) ◽

pp. 198 ◽

Cited By ~ 2

Author(s):

◽

Keyword(s):

Hepatitis C ◽

Viral Hepatitis ◽

Shear Wave ◽

Shear Wave Elastography ◽

Chronic Viral Hepatitis ◽

Core Antigen ◽

Direct Acting Antivirals ◽

Viral Hepatitis C ◽

Direct Acting ◽

Chronic Viral Hepatitis C

Download Full-text

Анализ отдаленной эффективности противовирусных препаратов прямого действия в терапии хронического вирусного гепатита С

Dalʹnevostočnyj medicinskij žurnal ◽

10.35177/1994-5191-2020-2-14-17 ◽

2020 ◽

pp. 14-17

Keyword(s):

Hepatitis C ◽

Viral Hepatitis ◽

High Efficiency ◽

Chronic Viral Hepatitis ◽

Direct Acting Antiviral ◽

Treatment Regimens ◽

Viral Hepatitis C ◽

Direct Acting ◽

And Control ◽

Chronic Viral Hepatitis C

Long-term eﬃcacy of direct-acting antiviral drugs (DAAD) was evaluated in 44 patients with chronic viral hepatitis C who had been receiving therapy at the Khabarovsk and Kamchatka centers for the prevention and control of AIDS and infectious diseases from 2015 to 2018. The data were evaluated through a retrospective analysis of ambulatory patient records and control in the form of a qualitative detection of viral RNA by a highly sensitive PCR method. According to the results of the analysis, 41 out of 44 patients (93,18 %) managed to achieve a stable virological response (SVR 24), which remains stable at present (p<0,05). Three of the studied patients had a relapse, probably associated with incorrect treatment regimens and the presence of cogenotypes. The data obtained indicate a high eﬃciency of DAAD in the treatment of chronic viral hepatitis C in the Khabarovsk and Kamchatka territories.

Download Full-text